Drug development is time-and cost-intensive and, despite extensive efforts, still hampered
by the limited value of current preclinical test systems to predict side effects, including …

Cardiac excitation–contraction coupling (ECC) is the orchestrated process of initial myocyte
electrical excitation, which leads to calcium entry, intracellular trafficking, and subsequent …

Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise
biomedicine. Global burden of heart failure will soon reach USD $90 bn, while unexpected …

Tissue engineers and stem cell biologists have made exciting progress toward creating
simplified models of human heart muscles or aligned monolayers to help bridge a …

Recent advances in the understanding and use of pluripotent stem cells have produced
major changes in approaches to the diagnosis and treatment of human disease. An obstacle …

Engineered 3D cardiac tissue constructs (ECTCs) can replicate complex cardiac physiology
under normal and pathological conditions. Currently, most measurements of ECTC …

Cardiomyocytes derived from human embryonic stem cells (hESC-CMs) are regarded as a
promising source for regenerative medicine, drug testing and disease modeling …

The generation of human pluripotent stem cell (hPSC)-derived ventricular progenitors and
their assembly into a 3-dimensional in vivo functional ventricular heart patch has remained …

Cardiomyocytes from human induced pluripotent stem cells (hiPSC-CMs) are the most
promising human source with preserved genetic background of healthy individuals or …

Traditional drug discovery is an inefficient process. Human pluripotent stem cell‐derived
cardiomyocytes can potentially fill the gap between animal and clinical studies, but …